Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Pharmacogenetics of nonsteroidal anti-inflammatory drugs

“…The trial utilized for the approval process was the Therapeutic Arthritis Research and Gastrointestinal Events Trial (TARGET). 33,34 This trial enrolled more than 18 000 subjects Z50 years of age who suffered from osteoarthritis. An independent case-control genome-wide association trial was conducted utilizing the patients from the TARGET trial.…”

NSAIDs and Peptic Ulcer Disease

“…At 6 months, rofecoxib was associated with a significantly lower incidence of GI events (2.1 vs. 4.5%, P < 0.001), and GI complications (0.6 vs. 1.42 %, P = 0.005). The TARGET study (Schnitzer et al, 2004) compared lumiracoxib with traditional NSAIDs in patients with osteoarthritis. After 1 year, a significant reduction in ulcer complication rates was noted for lumiracoxib among the entire study population (0.3 vs. 0.9%), as well as among those who were not taking aspirin (0.2 vs. 0.9%), but not in those taking aspirin.…”

The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks

“…Reproduced from reference 7 with permission patients taking acetylsalicylic acid, likely because they have a higher baseline risk. The coadministration of acetylsalicylic acid appears to eliminate most of the benefit of reduced gastrointestinal complications with a coxib compared with a tNSAID (18,23). Among patients at lower risk who could ethically enter a trial of low-dose acetylsalicylic acid, the loss of the gastrointestinal benefit of coxibs over tNSAIDs would eliminate most of the rationale for their use.…”

“…In a study that randomly assigned 1671 postcoronary artery bypass patients to valdecoxib plus parecoxib, valdecoxib alone or placebo, the RR for cardiovascular events over 30 days was 3.7 (P=0.03) for the combination and 2.0 (P=0.31) for valdecoxib alone (8). In a more recent trial of lumiracoxib (22,23), the RR for serious cardiovascular events was 0.76 for lumiracoxib versus ibuprofen and 1.46 for lumiracoxib versus naproxen, but neither RR was statistically significant.…”